N/A Completed N=279 Randomized Single-blind Treatment

Improving Urinary Continence and Quality of Life in Prostate Cancer Patients

Urinary Incontinence

Source: ClinicalTrials.gov NCT01365182 ↗

Enrolled (actual)

279

Serious AEs

1.2%

Results posted

Oct 2022

Primary outcomePrimary: Amount of Urinary Leakage — 23.2; 22.3; 31.5; 11 grams

Summary

This intervention program combines biofeedback PFME with a telephone or support group intervention to treat persistent urinary incontinence (UI). The study's primary aims are to improve continence, quality of life, and mood through enhancing adherence to PFME and self-management of incontinence symptoms. The secondary aims are to examine the physiological effects and cost effectiveness of the proposed interventions.

Outcome Measures

Outcome	Result	p-value
PRIMARY Amount of Urinary Leakage	23.2; 22.3; 31.5; 11; 23.2; 17.9	—
PRIMARY Frequency of Daily Urinary Leakage	3.2; 2.9; 2.7; 2.8; 1.8; 1.7	—

Eligibility Criteria

Inclusion Criteria

Have been diagnosed with early stage (I-III) prostate cancer.
Have completed cancer treatments six months prior.
Presence of incontinence symptoms

Exclusion Criteria

Receiving hormonal treatment.
Urinary tract infection or urinary retention.
Cognitive impairment.
Having an implant

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01365182). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.